---
schema_version: "secwatch.filing_event.v1"
accession: "0001367644-25-000179"
form_type: "8-K"
ticker: "EBS"
cik: "0001367644"
company_name: "Emergent BioSolutions Inc."
filed_at: "2025-08-06T23:59:59+00:00"
generated_at: "2026-05-17T19:01:00.822415+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Emergent BioSolutions Q2 revenue $140.9M, beats guidance; raises FY profitability outlook

## Summary
- Q2 revenue $140.9M (above Q2 guidance by $21M); net loss improved to $12.0M from $283.1M loss a year ago.
- Adjusted EBITDA swung to $28.5M from ($10.1M) loss; adjusted gross margin expanded to 49% from 26%.
- Naloxone revenue down 44% to $67.5M; Smallpox MCM up 127% to $40.6M; Anthrax MCM down 70%.
- Raised FY2025 adjusted EBITDA guidance to $175-$200M (prev. $150-$200M); adjusted gross margin 50-52%.
- Secured $65M multi-year NARCAN contract with Ontario Ministry of Health and $114.3M in contract modifications.

## SEC filing metadata
- accession: 0001367644-25-000179
- form_type: 8-K
- ticker: EBS
- cik: 0001367644
- company_name: Emergent BioSolutions Inc.
- filed_at: 2025-08-06T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1367644/000136764425000179/0001367644-25-000179-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1367644/000136764425000179/ebs-20250806.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001367644-25-000179
- JSON: https://secwatch.observer/filing/0001367644-25-000179.json
- Plain text: https://secwatch.observer/filing/0001367644-25-000179.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.